technology coins- Top Featured

Be cautious about high-end stocks stepping backBe cautious about high-end stocks stepping back

Be cautious about high-end stocks stepping backLast Friday's market performance was full of changes and opportunities. The daily limit is less than expected, and the high-low switch is obvious, which shows the caution and keenness of market funds. WuXi PharmaTech benefited from the MG Medicine Act, but it failed to continue to strengthen, and the pressure and market reaction were clear at a glance.At midday, the key analysis targets are for reference only, and accordingly, the operation is at its own risk.

In the concept of humanoid robot, Fenda Technology's performance in the morning is particularly eye-catching. Washed the chips that should have been washed last Friday and made more backhand in the morning, which is not only a response to the market, but also a display of its own strength. The intra-day dish-washing relay race in the morning of the construction industry has made people see the firmness and persistence of the robot concept fund. From the point of view of the index, the lack of energy and follow-up led to the index's high and low today, which is also within our expectations. The structural market continues to unfold, keeping a keen perception of the market at all times.In the afternoon, we will see if Wuxi PharmaTech has a chance to reply, which will have an important impact on the continued adjustment of the market or index. The change of daily limit data also deserves close attention. However, in general, the decline of high-level stocks, especially the influence of core stocks such as CAMBRIAN, can not be ignored. The market is full of changes and opportunities, and we need to be vigilant and keen at all times in order to capture our own opportunities in it.Last Friday's market performance was full of changes and opportunities. The daily limit is less than expected, and the high-low switch is obvious, which shows the caution and keenness of market funds. WuXi PharmaTech benefited from the MG Medicine Act, but it failed to continue to strengthen, and the pressure and market reaction were clear at a glance.